• 充值
  • 会员
  • 职称材料
搜期刊
刊名

文献信息

  • 任意字段
  • 主题词
  • 篇关摘
  • 篇名
  • 关键词
  • 摘要
  • 作者
  • 第一作者
  • 作者单位
  • 刊名
  • 中图分类号
  • 学科分类号
  • DOI
  • 基金
文献检索

新西兰
投稿预审
Drugs 中科院1区 JCR:Q1 SCIE PubMed JST
发文量 17,332
被引量 452,002
影响因子(2025版) 12.449

Stay up to date with the latest developments in therapeutics by reading the world’s most respected source of authoritative drug information. For 50 years Drugs has been the definitive journal of drugs and therapeutics, promoting optimum pharmacotherapy by publishing reviews and original research authored by leading international clinicians and researchers to support clinical decision-making. Through a rigorous and comprehensive program of peer-reviewed evaluations, Drugs provides detailed and objective analysis covering the full spectrum of new and established drug therapies in all disease areas. As a hybrid journal, Drugs does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require. This is achieved via the Springer Open Choice™ initiative. More information about this optional route to open access and the associated article processing charge can be found by clicking on the ‘How to publish with us, including Open Access’ link below. Drugs offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.

  • 主办单位： ADIS INT LTD
  • 出版地区： AUCKLAND
  • 出版周期： 半月刊
  • 别名： DRUGS;药物;DRUGS
  • 国际标准连续出版物号/电子版： ISSN 0012-6667 / EISSN 1179-1950
  • 创刊时间： 1971年
热门主题：

Pharmacokinetic PropertiesPharmacological PropertiesTherapeutic EfficacyPlacebo-controlled TrialTherapeutic UseTreatment of PatientsTreatment of Hypertensiononce DailyClinical Trialsin Vitro ActivityHypertensive PatientsCombination TherapyBlood PressureHealth-related Quality of LifePatients with HypertensionPatients with Mild to Moderate HypertensionDrugsDiabetes MellitusDrug TreatmentTherapeutic Potential

收录汇总 栏目浏览 期刊详情
收录汇总
出版文献
期刊详情
新发布(2025版)
分析评价
  • 1
  • 2
  • 3
  • 4
  • 9
目录
封面
2017年10期

2017年10期

客服咨询
投稿相关：023-63416211
撤稿相关：023-63012682
查重相关：023-63506028
重庆维普资讯有限公司 渝B2-20050021-1 渝公网备 50019002500403
违法和不良信息举报中心   举报邮箱：jubao@cqvip.com   互联网算法推荐专项举报：sfjubao@cqvip.com    网络暴力专项举报: bljubao@cqvip.com
网络出版：（署）网出证（渝）字第014号    出版物经营许可证：新出发2018批字第006号